Bizarre Patents
A portable partition for use in an automobile having a seat with a seat bench and a seat backrest.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8183388 | Androgen receptor modulator and uses thereof The present invention relates to the compound of the formula: to pharmaceutical compositions comprising the compound of Formula (I); and to methods for treating or preventing hypogonadism, osteoporosis, osteopenia, sarcopen... | 05/22/2012 |
| 8183346 | Anti-ferroportin 1 monoclonal antibodies and uses thereof Provided are monoclonal antibodies and antigen-binding fragments thereof that bind to, and inhibit the activity of human FPN1, and which are effective in maintaining or increasing the transport of iron out of mammalian cells and/or maintaining or increasing the leve... | 05/22/2012 |
| 8183340 | GLP-1 pegylated compounds The invention provides GLP-1 compounds coupled to two polyethylene glycol molecule or derivative thereof, resulting in a biologically active peptide with an extended half-life and a slower clearance when compared to that of unPEGylated peptide. These PEGylated GLP-1... | 05/22/2012 |
| 8178528 | Histamine H3 receptor agents, preparation and therapeutic uses The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof which have histamine—H3 receptor antagonist or inverse agonist activity, as well as methods and intermediates for preparing such compounds. In another embod... | 05/15/2012 |
| 8173821 | Serotonin and norepinephrine reuptake inhibitor A serotonin and norepinephrine reuptake inhibitor of the formula: its uses, and methods for its preparation are described. ... | 05/08/2012 |
| 8173695 | Kappa selective opioid receptor antagonist A selective kappa opioid receptor antagonist useful for treating ethanol use disorder withdrawal and anxiety, and/or depression, or schizophrenia as independent comorbid conditions. ... | 05/08/2012 |
| 8173124 | Method to treat using antagonistic anti-hTNFSF13b human antibodies Human monoclonal antibodies that specifically bind to TNFSF13b polypeptides are disclosed. These antibodies have high affinity for hTNFSF13b (e.g., KD=10−8 M or less), a slow off rate for TNFSF13b dissociation (e.g., Koff=10âˆ... | 05/08/2012 |
| 8168659 | 1, 5-diphenyl-3-benzylamino-1, 5-dihydropyrrolidin-2-one as CB1 receptor modulators Compounds and pharmaceutical compositions comprising compounds of the Formula as CB1 receptor inverse agonists useful for reducing body weight in mammals, treating cognitive impairment associated with schizophren... | 05/01/2012 |
| 8153807 | Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 The present invention discloses novel compounds of Formula I: (I) having 11-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I,... | 04/10/2012 |
| 8153683 | Methods of treatment using a prodrug of an excitatory amino acid This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psych... | 04/10/2012 |
| 8153624 | Compounds and methods for modulating FXR Compounds of formula (I): formula (I) wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and diseases related to dyslipidemia. ... | 04/10/2012 |
| 8148534 | Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 The present invention discloses novel compounds of Formula I: (I) possessing 11β-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Form... | 04/03/2012 |
| 8148498 | DKK-1 antibodies The invention provides human engineered antibodies, antigen-binding fragments thereof, that bind to, and inhibit the activity of, human DKK-1, and which are effective in treating diseases in which pathogenesis is mediated by DKK-1. ... | 04/03/2012 |
| 8148387 | AKT and P70 S6 kinase inhibitors The present invention provides AKT and p70 S6 kinase inhibitors of the formula: The present invention also provides pharmaceutical compositions comprising compounds of Formula I, uses of compounds of Formula I and methods of ... | 04/03/2012 |
| 8133907 | Pyridine derivatives as dipeptedyl peptidase inhibitors The present invention is directed to compounds of formula (I) or a pharmaceutically acceptable salt thereof; wherein A is (1); X is selected from CH, CF and N; R5 is selected from H, C1-C6 alkyl, C1-C6 fluoroalkyl, and —... | 03/13/2012 |
| 8129518 | Synthetic polysaccharide antigens for immunological intervention in disease Provided are synthetic polysaccharide antigens (SPAs) with anti-inflammatory or inflammatory immunomodulatory properties, depending on their structure. Also provided are compositions comprising these SPAs, and methods of using these SPAs and compositions to either p... | 03/06/2012 |
| 8128927 | Methods of using TGF-β 1 binding compositions TGF-beta 1 binding compositions and reagents related thereto are provided. Methods of using such compositions for therapeutic purpose are also provided. ... | 03/06/2012 |
| 8124776 | Process and intermediates for preparing arzoxifene The present invention provides for novel compounds of formula I wherein X is S or S(O); R1 and R2 are each independently selected from the group consisting of —CH2CH3 and phenyl; or R1 and R2 combin... | 02/28/2012 |
| 8114901 | Crystalline 2,5-dione-3-(1-methyl-1H-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1H-indol-3-yl]-1H-pyrrole mono-hydrochloride The present invention relates to crystalline 2,5-dione-3-(1-methyl-1H-indol-3-yl)-4-[1-(pyridin-2-yl-methyl)piperidin-4-yl]-1H-indol-3-yl]-1H-pyrrole mono-hydrochloride salt, a pharmaceutical formulation containing said salt and to methods for treating cancer and fo... | 02/14/2012 |
| 8114872 | Triazolyl aminopyrimidine compounds The present invention provides triazolyl aminopyrimidine compounds useful in the treatment of cancer. ... | 02/14/2012 |
| 8114854 | Crystalline forms of gemcitabine amide prodrug, compositions and use thereof The present invention relates to novel crystal forms of an amide prodrug of gemcitabine, compositions thereof and methods for using. ... | 02/14/2012 |
| 8110580 | Thiophene pyrazolopyrimidine compounds The present invention relates to compounds of Formula (I), pharmaceutical compositions thereof, and the use of such compounds as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric and neuroendocrine disorders, neurological d... | 02/07/2012 |
| 8110191 | Anti-IL-17 antibodies Anti-IL-17 antibodies are identified that are characterized as having a high affinity and slow off rate for human IL-17. The antibodies of the invention may be chimeric, humanized or fully human antibodies, immunoconjugates of the antibodies or antigen-binding fragm... | 02/07/2012 |
| 8106090 | 1-amino linked compounds The present invention is directed to compounds of formula (I): or a pharmaceutically acceptable salt thereof; wherein A is (II); X is selected from CH, CF and N, R8 is selected from H, C1-C6 alkyl, aryl, heteroaryl, C1-C6 ... | 01/31/2012 |
| 8106077 | Compounds and methods for modulating FXR Compounds of formula (I) wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and related diseases. ... | 01/31/2012 |
| 8101764 | MCH receptor antagonists The present invention relates to a melanin concentrating hormone antagonist compound of formula (I): wherein R1, Ra, Rb, R2, L1, R3, R4 and R5 are as defined, or a pharmaceutical... | 01/24/2012 |
| 8101761 | (E)-N-{3-[1-(8-fluoro-11H-10-OXA-1-AZA-dibenzo [A,D] cyclohepten-5ylidene)-propyl]-phenyl}-methanesulfonamide as glucocorticoid receptor modulator for the treatment of rheumatoid arthritis The present invention provides Compound (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising Compound (I) in combination with one or more pharmaceutically acceptable carriers, excipients, or diluents; and discloses methods for th... | 01/24/2012 |
| 8101760 | Glucocorticoid receptor modulator and methods of use The present invention provides Compound (I): Compound (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising Compound (I) in combination with one or more pharmaceutically acceptable carriers, excipients, or diluents; and methods fo... | 01/24/2012 |
| 8101638 | 6-substituted nicotinamide derivatives as opioid receptor antagonists A compound of the formula (I) or a pharmaceutically acceptable salt, enantiomer, racemate, diasteromers or mixtures thereof, or a solvate thereof, formulations and methods of use thereof, as opioid receptor antagonists are disclosed wherein the variables are as desc... | 01/24/2012 |
| 8101628 | Imidazolidinonyl aminopyrimidine compounds for the treatment of cancer The present invention provides novel imidazolidinonyl aminopyrimidine compounds believed to have clinical use for treatment of cancer through inhibiting Plk1. wherein: R1 hydrogen, hydroxy, halo, methyl, C1-C2 alkoxy, amino, or methy... | 01/24/2012 |
| 8097652 | AMPA receptor potentiators The present invention relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof which is useful for the treatment of conditions associated with glutamate hypofunction, such as psychiatric and neurological disorders. | 01/17/2012 |
| 8093383 | P70 S6 kinase inhibitors The present invention provides p70 S6 kinase inhibitors of the formula: pharmaceutical formulations comprising them, and methods for their use. ... | 01/10/2012 |
| 8093353 | Agents for treatment of HCV and methods of use An amphipathic helix at the approximate N-terminus of Hepatitis C virus (HCV) nonstructural proteins mediates the association of these proteins with cytoplasmic membranes in infected cells. This association is essential for replication. Thus, assessing the ability o... | 01/10/2012 |
| 8093302 | Substituted tetralins as selective estrogen receptor-β agonists The present invention relates to novel tetralin ER-β agonist compounds, pharmaceutical compositions thereof, and use of these compounds to treat a ER-β mediated disease such as nocturia, obstructive uropathy, benign prostatic hypertrophy, obesity, dementia, hypert... | 01/10/2012 |
| 8088800 | 4-(5-aminomethyl)-indole-1-ylmethyl)-benzamide derivatives and related compounds as opioid receptor antagonists for the treatment of obesity The present invention relates to compounds of formulae (I) and (II) useful as opioid receptor antagonists for the treatment of obesity, wherein p is 0, 1, or 2; y is 0, 1, or 2; and z is 0, 1, or 2; X1 is CH2, CH, or N; to form a indolinyl, ind... | 01/03/2012 |
| 8088776 | Biphenyl amide lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 The present invention discloses novel compounds of Formula I: possessing 11 β-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula... | 01/03/2012 |
| 8084489 | Glucagon receptor antagonists, preparation and therapeutic uses The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof which have glucagon receptor antagonist or inverse agonist activity, as well as methods of using these compounds and intermediates and methods for preparing s... | 12/27/2011 |
| 8084261 | Method for predicting responsiveness to a pharmaceutical therapy for obesity Methods for using TRL V6 as a biomarker for the modulation of triglyceride and/or lipoprotein metabolism in a mammal induced by a weight loss pharmaceutical agent. The biomarker may be used for determining if an individual patient will likely respond favorably to a ... | 12/27/2011 |
| 8076514 | Phenyl compounds and their use in the treatment of Type II diabetes The present invention is directed to compounds of formula (I) or a pharmaceutically acceptable salt thereof; wherein A is (xx); X is selected from CH, CF and N, R5 is selected from H, C1-C6 alkyl, C1-C6 fluoroalkyl, and â€... | 12/13/2011 |
| 8076374 | Glucagon receptor antagonists, preparation and therapeutic uses The present invention discloses novel compounds of Formula (I), or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention d... | 12/13/2011 |
